Creative Biolabs performs targeted isolation and screening of B. pullicaecorum from human, animal, or environmental samples using strict anaerobic techniques. Enrichment strategies, selective media, and multi-parameter primary screening help identify robust B. pullicaecorum strains with desirable butyrate production, growth kinetics, and technological properties for downstream R&D.
For each B. pullicaecorum isolate, identification combines 16S rRNA gene sequencing, genome-based taxonomic analysis, and chemotaxonomic profiling. This multi-layer approach differentiates B. pullicaecorum from closely related Oscillospiraceae members and documents strain identity for regulatory dossiers, IP support, and future comparative studies.
Dedicated anaerobic fermentation platforms support lab-scale to pilot-scale production of B. pullicaecorum. Creative Biolabs optimizes pH, carbon sources, redox control, and agitation to maximize viable counts and butyrate yield, while monitoring key metabolites and stability attributes that influence downstream formulation and functional evaluation.
Mechanistic studies interrogate how B. pullicaecorum and its metabolites modulate gut epithelial integrity, SCFA transporter and receptor expression, and host signaling pathways. Creative Biolabs designs bespoke in vitro and ex vivo assays to map mode of action, including butyrate-responsive gene signatures, barrier function readouts, and host-microbe interaction endpoints.
B. pullicaecorum–conditioned media and purified metabolites are evaluated in immune co-culture systems, including dendritic cells, T cell subsets, and epithelial–immune models. These platforms quantify cytokine profiles, Th17/Treg balance, and chemokine production, supporting projects in gut inflammation, bone–gut axis research, and food allergy immunology.
Carbohydrate utilization and SCFA output of B. pullicaecorum are characterized using defined substrates (e.g., dietary fibers, prebiotics) and high-resolution metabolite analytics. This service links specific carbohydrate sources to butyrate production profiles, informing synbiotic design, dietary intervention studies, and formulation strategies.
Creative Biolabs supports the development of B. pullicaecorum formulations suitable for research use and pre-clinical evaluation, including encapsulated and stabilized formats compatible with oxygen-sensitive organisms. Encapsulation and excipient selection are guided by published stability work on B. pullicaecorum next-generation probiotic candidates.
B. pullicaecorum strains are profiled using a safety panel that can include genome-based virulence and resistance gene screening, hemolysis assays, antibiotic susceptibility testing, and in vitro cytotoxicity assessments. These data support safe-by-design development of B. pullicaecorum as a model organism, research tool, or candidate for advanced microbiome applications.
